Yesterday, Epizyme's abstract to be presented at the International Conference on Malignant Lymphoma indicated a slip of the median duration of response in EZH2 wild type patients, H.C. Wainwright analyst Andrew Fein tells investors in a research note. He believes the stock overreacted due to concern "about a possible regulatory hiccup and a potentially narrower label." The analyst, however, continues to believe tazemetostat's data package should support a broad label in follicular lymphoma. He reiterates a Buy rating on Epizyme with a $25 price target.